Repligen (RGEN) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.

8 brokers have issued 1-year price objectives for Repligen's shares. Their RGEN share price forecasts range from $157.00 to $275.00. On average, they anticipate the company's share price to reach $208.56 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $169.31 at the beginning of 2023. Since then, RGEN stock has decreased by 4.2% and is now trading at $162.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our RGEN earnings forecast.

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.05. The biotechnology company had revenue of $182.70 million for the quarter, compared to analyst estimates of $181.43 million. Repligen had a trailing twelve-month return on equity of 9.14% and a net margin of 21.58%. The firm's quarterly revenue was down 11.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.92 EPS.

ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco Dynamic Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), WisdomTree BioRevolution Fund (WDNA) and BlackRock Future Health ETF (BMED).

Repligen updated its FY23 earnings guidance on Tuesday, May, 2nd. The company provided EPS guidance of $2.35-$2.42 for the period, compared to the consensus EPS estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million.

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.76%), State Street Corp (2.94%), Sands Capital Management LLC (2.90%), Wellington Management Group LLP (2.68%), Brown Capital Management LLC (2.59%) and Artisan Partners Limited Partnership (2.19%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGEN stock can currently be purchased for approximately $162.19.

Repligen (NASDAQ:RGEN) has a market capitalization of $9.03 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $2.95 on an earnings per share basis.

The company employs 2,025 workers across the globe.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.